araag2/HINT huggingface dataset:
Clinical trial NCT03074331 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  HCV RNA detected at screening

          -  Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy

          -  Classification as treatment naïve or treatment experienced. Approximately 20% may be
             treatment-experienced.

          -  Cirrhosis determination (approximately 20% may have cirrhosis)

          -  Females of childbearing potential must have a negative urine pregnancy test at
             Screening and on Day 1 prior to enrollment.

          -  Male individuals and female individuals of childbearing potential who engage in
             heterosexual intercourse must agree to use protocol specified method(s) of
             contraception as described in the study protocol

          -  Lactating females must agree to discontinue nursing before the study drug is
             administered

          -  Adults must be able to comply with the dosing instructions for study drug
             administration and able to complete the study schedule of assessments

        Key Exclusion Criteria:

          -  Current or prior history of any of the following:

               -  Clinically-significant illness (other than HCV) or any other major medical
                  disorder that may interfere with individual's treatment, assessment or compliance
                  with the protocol

               -  Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal
                  hemorrhage)

               -  Liver transplantation

               -  Hepatocellular carcinoma (HCC) (as determined by appropriate imaging at screening
                  for those with cirrhosis) or current malignancy for which the patient is
                  receiving treatment or which may interfere with individual's treatment,
                  assessment or compliance with the protocol.

          -  Screening laboratory parameters outside of defined threshold

          -  Prior exposure to HCV NS5A inhibitor

          -  Pregnant or nursing female

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Use of any prohibited concomitant medications as described in study protocol

          -  Known hypersensitivity to VEL, SOF, or formulation excipients

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT03078478 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria: - Male or female, age above or equal to 18 years at the time of signing
        informed consent. - Subjects fulfilling at least one of the below criteria (For this
        inclusion criterion the aim is to include minimum 80% of individuals with a previous
        episode of hypoglycaemia (criterion e). The remaining subjects will have to fulfil at least
        one of criteria a-d.): - a) Experienced at least one severe hypoglycaemic episode within
        the last year (according to the ADA definition, April 2013 (An episode requiring assistance
        of another person to actively administer carbohydrate, glucagon, or take other corrective
        actions. Plasma glucose concentrations may not be available during an event, but
        neurological recovery following the return of plasma glucose to normal is considered
        sufficient evidence that the event was induced by a low plasma glucose concentration.). -
        b) Moderate chronic renal failure, defined as glomerular filtration rate 30 - 59
        mL/min/1.73 m^2 per CKD-EPI by central laboratory analysis. - c) Hypoglycaemic symptom
        unawareness (History of impaired autonomic responses (tremulousness, sweating,
        palpitations, and hunger) during hypoglycaemia). - d) Treated with insulin for more than 5
        years. - e) Episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode
        with low glucose measurement (equal to or below 70 mg/dL [equal to or below 3.9 mmol/L]))
        within the last 12 weeks prior to Visit 1 (screening). - Subjects diagnosed (clinically)
        with type 2 diabetes mellitus. - Treated with basal only insulin (once daily or twice-daily
        insulin (insulin detemir; insulin glargine 100 U/mL, biosimilar of insulin glargine 100
        U/mL or insulin Neutral Protamine Hagedorn)) equal to or above 90 days prior to the day of
        screening with or without any of the following anti-diabetic drugs with stable doses for
        equal to or above 90 days prior to screening: - a) Metformin - b) Dipeptidyl peptidase -4
        inhibitor - c) Sodium-glucose co-transporter 2 inhibitor - d) Alpha-glucosidase-inhibitors
        (acarbose) - e) Thiazolidinediones - f) Marketed oral combination products only including
        the products listed in criteria 5a-5e - HbA1c equal to or below 9.5% (80 mmol/mol) at
        screening by central laboratory analysis. - BMI equal to or below 45 kg/m^2. Exclusion
        Criteria: - Treatment with any medication for the indication of diabetes or obesity other
        than stated in the inclusion criteria in a period of 90 days before the day of screening
Clinical trial NCT03081208 (phase 3, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: nolasiban 900mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Indicated for IVF/ICSI in the context of assisted reproductive technology (ART)

          -  Follow a gonadotropin releasing hormone (GnRH) antagonist protocol, single injection
             of human chorionic gonadotropin (hCG) for triggering final follicular maturation and
             luteal phase support with vaginal micronized progesterone.

          -  Single, fresh D3 or D5 embryo transfer

        Key Exclusion Criteria:

          -  Frozen-thawed embryo transfer

          -  More than 20 oocytes in the current controlled ovarian hyperstimulation (COH) cycle

          -  Serum P4 greater than 1.5 ng/mL on the day of hCG administration
Clinical trial NCT03090100 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: guselkumab, placebo, secukinumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of plaque-type psoriasis (with or without [Psoriatic Arthritis]PsA)
             for at least 6 months before the first administration of study drug

          -  A woman of childbearing potential must have a negative urine pregnancy test at
             screening and at Week 0 and agree to urine pregnancy testing before receiving
             injections

          -  Agree not to receive a live virus or live bacterial vaccination during the study, or
             within 3 months after the last administration of study drug

          -  Agree not to receive a Bacille Calmette-Guérin (BCG) vaccination during the study, or
             within 12 months after the last administration of study drug

          -  Agree to avoid prolonged sun exposure and avoid use of tanning booths or other
             ultraviolet light sources during study

        Exclusion Criteria:

          -  Has a history or current signs or symptoms of severe, progressive, or uncontrolled
             renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,
             hematologic, rheumatologic, psychiatric, or metabolic disturbances

          -  Has previously received guselkumab or secukinumab

          -  Has a history of chronic or recurrent infectious disease, including but not limited to
             chronic renal infection, chronic chest infection (example bronchiectasis), recurrent
             urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis),
             fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin
             wounds or ulcers

          -  Has a history of lymphoproliferative disease, including lymphoma; a history of
             monoclonal gammopathy of undetermined significance; or signs and symptoms suggestive
             of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly

          -  Is unable or unwilling to undergo multiple venipunctures because of poor tolerability
             or lack of easy access to veins
Clinical trial NCT03091673 (phase 3, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: glucagon
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosed with T1D for at least 6 months at Screening.

          -  current usage of daily insulin treatment.

        Exclusion Criteria:

          -  pregnant or nursing

          -  renal insufficiency

          -  hepatic synthetic insufficiency

          -  aspartate or alanine aminotransferase > 3 times the upper limit of normal

          -  hematocrit less than or equal to 30%

          -  use of > 2.0 U/kg total insulin dose per day

          -  inadequate venous access

          -  current seizure disorder

          -  history of pheochromocytoma or disorder with increased risk of pheochromocytoma

          -  history of insulinoma

          -  history of glycogen storage disease.

          -  active use of alcohol or drugs of abuse

          -  administration of glucagon within 14 days of the first treatment visit

          -  participation in other studies involving an investigational drug or device within 30
             days
Clinical trial NCT03092375 (phase 3, status: completed)
Conditions: hepatitis c, hcv
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: glecaprevir/pibrentasvir (g/p) 300mg/120mg, ribavirin 200mg tablet
SMILES: [H][C@](C)(OC)[C@]([H])(N=C(O)OC)C(=O)N1CCC[C@@]1([H])C1=NC2=C(N1)C=C(F)C(=C2)[C@@]1([H])CC[C@@]([H])(N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@]2([H])CCCN2C(=O)[C@@]([H])(N=C(O)OC)[C@@]([H])(C)OC)C=C1F, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female at least 18 years of age at time of screening.

          2. A history of previous treatment with an NS5A-inhibitor plus sofosbuvir therapy ± RBV
             for chronic HCV genotype 1 infection.

          3. Treatment must have been completed at least 1 month prior to Screening Visit.

          4. Screening laboratory result indicating chronic HCV GT1 infection. Subjects must be
             able to understand and adhere to the study visit schedule and all other protocol
             requirements and must voluntarily sign and date an informed consent.

        Exclusion Criteria:

          1. History of severe, life-threatening or other significant sensitivity to any drug.

          2. Female who is pregnant, planning to become pregnant during the study or breastfeeding;
             or male whose partner is pregnant or planning to become pregnant during the study.

          3. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or
             anti-human immunodeficiency virus antibody (HIV Ab) in patient without known history
             of HIV infection.

          5. HCV genotype performed during screening indicating co-infection with more than one HCV
             genotype.

          6. History or presence of liver decompensation.
Clinical trial NCT03093324 (phase 3, status: completed)
Conditions: relapsing remitting multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: alks 8700, dimethyl fumarate
SMILES: [H]\C(=C(\[H])C(=O)OC)C(=O)OC
Eligibility criteria:

        Key Inclusion Criteria:

          -  Capable of understanding and complying with the protocol

          -  Has a confirmed diagnosis of RRMS

          -  Neurologically stable with no evidence of relapse within 30 days prior to
             randomization

          -  Agrees to use an acceptable method of contraception for the duration of the study and
             for 30 days after any study drug administration, or is surgically sterile or
             post-menopausal

        Key Exclusion Criteria:

          -  Have any finding(s) that would compromise the safety of the subject, affect the
             subject's ability to adhere to the protocol visit schedule or to fulfill visit
             requirements, or would make the subject unsuitable for participation in the study

          -  Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS

          -  History of clinically significant cardiovascular, pulmonary, GI, dermatologic,
             psychiatric, neurologic (other than MS), endocrine, renal, and/or other major disease
             that would preclude participation in a clinical trial

          -  History of GI surgery (except appendectomy that occurred more than 6 months prior to
             screening

          -  History of clinically significant recurring or active gastrointestinal symptoms (eg,
             nausea, diarrhea, dyspepsia, constipation) within 3 months of screening

          -  Chronic use (7 days) of medical therapy to treat any GI symptoms within 1 month of
             screening Has a clinically significant medical condition or observed abnormality at
             screening

          -  History of a myocardial infarction, including a silent myocardial infarction or
             unstable angina

          -  History of clinically significant drug or alcohol abuse within the past year prior to
             screening

          -  Clinically significant history of suicidal ideation or suicidal behavior in the last
             12 months

          -  Subject is pregnant or breastfeeding or plans to become pregnant or begin
             breastfeeding at any point during the study and for 30 days after any study drug
             administration

          -  Prior use of Dimethyl Fumarate (DMF)

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT03095456 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease, copd, low peak inspiratory flow rate (pifr)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: revefenacin, placebo for revefenacin, placebo for spiriva handihaler®
SMILES: CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older with a diagnosis of COPD.

          -  Subject has a current or past cigarette smoking history (or equivalent for cigar or
             pipe smoking history) of at least 10 pack-years.

          -  Subject is willing and able to provide signed and dated written informed consent to
             participate prior to initiation of any study related procedures.

        Exclusion Criteria:

          -  Subject has a concurrent disease or condition that, in the opinion of the
             investigator, would interfere with continued study participation or confound the
             evaluation of safety and tolerability of the study drug.

          -  Subject has a history of reactions or hypersensitivity to inhaled or nebulized
             anticholinergics.

          -  Subject suffers from any medical condition that would preclude the use of inhaled
             anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic
             hyperplasia, bladder neck obstruction, or urinary retention.
Clinical trial NCT03097861 (phase 3, status: completed)
Conditions: chronic idiopathic constipation
ICD codes: K59.04
Drugs: lubiprostone, placebo
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Either has medically-confirmed diagnosis of chronic constipation (per Rome III), or
             meets the diagnosis as confirmed using the Rome III constipation module questionnaire
             during the Screening period.

          -  Is male or female, 18 or older years of age

          -  Should be on stable dose of fiber supplement or a concomitant medication for the
             indication of lowering blood pressure

        Exclusion Criteria:

          -  Has any gastrointestinal (GI) condition, other than constipation, affecting GI
             motility or defecation

          -  Is unable to eat or drink, take oral medications, or to hold down oral medications due
             to vomiting
Clinical trial NCT03103087 (phase 3, status: completed)
Conditions: heavy menstrual bleeding, uterine fibroid
ICD codes: G43.831, G43.839, G43.821, G43.829, N94.9, N94.89
Drugs: relugolix, estradiol/norethindrone acetate, relugolix placebo, estradiol/norethindrone acetate placebo
SMILES: CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, CC(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and
             dating the informed consent form.

          2. Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to
             38 days from the start of 1 menstrual period until the start of the next, by
             participant history for at least 3 months prior to the first screening visit.

          3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or
             transabdominal ultrasound performed during the screening period.

          4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL
             of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as
             measured by the alkaline hematin method during the screening period.

        Key Exclusion Criteria:

          1. Has transvaginal and/or transabdominal ultrasound during the screening period
             demonstrating pathology other than uterine fibroids that could be responsible for or
             contributing to the participant's heavy menstrual bleeding.

          2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.

          3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that
             precludes an adequate DXA measurement at the lumbar spine and proximal femur.

          4. Has a history of or currently has osteoporosis, or other metabolic bone disease,
             hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low
             traumatic (from the standing position) or atraumatic fracture (toe, finger, skull,
             face and ankle fractures are allowed). A history of successfully treated
             hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the
             participant's bone mineral density is within normal limits.

          5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone,
             teriparatide, denosumab, or any medication other than calcium and vitamin D
             preparations to treat bone mineral density loss.

          6. Has been a participant in an investigational drug or device study within the 1 month
             prior to the first screening visit.
Clinical trial NCT03108664 (phase 3, status: completed)
Conditions: dry eye disease
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: syl1001 ophthalmic solution, vehicle opthalmic solution
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Both genders

          -  ≥ 18 years old

          -  Give written informed consent to participate in the study after having been informed
             of the study design, objectives and possible derived risks

          -  Common symptoms of persistent, daily, moderate to severe dry eye lasting more than six
             months.

          -  Use of artificial tears

          -  VAS scale for eye discomfort/pain between 30 - 80

          -  CFS ≥ 2 and ≤ 4 on the Oxford scale

          -  TBUT < 10 seconds

          -  Hyperemia score ≥ 1 (McMonnies scale)

          -  Schirmer's test without anesthesia ≥ 2 and < 10 mm/5min in the eye

          -  Corrected visual acuity ≥ 0.7 logMAR

        Exclusion Criteria:

          -  Pregnant or breastfeeding females or those with a positive pregnancy test.

          -  Females of childbearing potential who will not use a medically acceptable
             contraceptive method from selection and during the whole study.

          -  Current relevant disease, including respiratory disease, cardiovascular, endocrine,
             neurological, haematological, renal, neoplasic, hepatopathy, gastrointestinal
             distress, hypertension, or infectious acute processes.

          -  Past history of a chronic o recurring condition that could interfere with study
             according to the investigator's judgement.

          -  Concomitant use of other drugs with analgesic activity by any route of administration
             at the enrolment period.

          -  Changes in any ocular and/or systemic concomitant medication one month prior to the
             study commencement and during the study development.

          -  Changes on the preestablished artificial tears dosage 15 days prior to the study
             commencement and during the study development.

          -  Cyclosporine treatment initiation or changes in cyclosporine dosage or dosing regimen
             during the 6 months prior to enrolment.

          -  Previous history of drug hypersensitivity.

          -  Use of contact lenses

          -  Case history of drug or alcohol abuse or dependence.

          -  Relevant abnormal laboratory results as judged by the investigator

          -  Previous refractive surgery

          -  Participation in a clinical trial within 2 months before the enrolment visit

          -  Relevant ocular pathology judged by the investigator.